Immune cell clues could unlock kidney disease treatment secrets

NCT ID NCT04095156

Recruiting now Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is investigating why some people with membranous nephropathy, a kidney disease, respond well to a treatment that depletes certain immune cells (B-cells) while others do not. Researchers will analyze blood samples from 86 patients and healthy volunteers to compare immune cell types and activity. The goal is to find biological markers that predict treatment success and better understand the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors predict which patients will benefit from B-cell depleting therapy, leading to more personalized treatment for membranous nephropathy.
What could go wrong: This is an observational study, not a treatment trial. It aims to gather knowledge, not test a new therapy. Results may not directly change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò"
RECRUITING

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.